×

Business / Stock Market

Medtronic's Evolut TAVR system shows "strong performance" at two years in low risk aortic stenosis patients

Published May 18 2021 at 1:24 PM GMT

Seeking Alpha @seekingalpha.com

Add to Collections
Report Post

Continue reading at seekingalpha.com

Key
Points

Medtronic's Evolut TAVR system shows "strong performance" at two years in low risk aortic stenosis patients.

Credit

Tags

Continue reading at seekingalpha.com

Posted in Business, Stock Market

Stats

Published May 18, 2021 1:24 PM GMT